Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 EUR | -8.31% | -8.59% | -7.45% |
Apr. 17 | Orapi SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | Orapi: Groupe Paredes holds almost 90% of the capital | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.41 for the 2024 fiscal year.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.45% | 41.45M | - | ||
+5.14% | 103B | A- | ||
-5.63% | 63.04B | A- | ||
+39.52% | 39.06B | B | ||
+12.91% | 37.58B | B | ||
+7.41% | 33.24B | A- | ||
+6.85% | 19.22B | B- | ||
+12.86% | 16.83B | C+ | ||
+16.93% | 14.96B | B- | ||
+7.73% | 15.03B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ORAP Stock
- Ratings ORAPI